PDCD1 and lung cancer: Notably, clinical studies suggested that the combined use of daily aspirin at doses ≥81 mg daily and anti‐PD‐1 is associated with more favorable outcomes (i.e., decreased progressive disease) also in nonsmall cell lung cancer, suggesting a synergistic effect determined by the concomitant decrease of the immunosuppressive PGE2 and PD‐1.